Introduction
============

The purpose of this study was to determine the effects of exogenous glucagon-like peptide 1 (GLP-1) on the glycaemic response to enteral nutrition in nondiabetic, critically ill patients. Exogenous GLP-1 lowers blood glucose concentrations in both healthy humans and patients with type 2 diabetes, via suppression of glucagon, stimulation of insulin secretion and slowing gastric emptying. As the humoral effects are glucose dependent, the use of GLP-1 is not associated with hypoglycaemia. The effects of GLP-1 on glycaemia in critical illness have hitherto not been evaluated.

Methods
=======

Seven, nondiabetic, critically ill patients (four males, three females; age 58 ± 6 years) received, on two separate days, intravenous GLP-1 (1.2 pmol/kg/min) or placebo between *t*= 0 and 270 minutes, in randomised double-blind fashion. Between *t*= 30 and 270 minutes a liquid nutrient was infused intra-duodenally at a rate of 1.5 kcal/min. Blood glucose, plasma insulin and glucagon concentrations were measured. Data are presented as the mean ± SEM. Statistical analyses were performed using the paired *t*test or repeated-measures ANOVA.

Results
=======

Compared with placebo, GLP-1 decreased peak glucose concentrations (10.1 ± 0.7 mmol/l vs. 12.7 ± 1.1 mmol/l; *P*= 0.01) and markedly attenuated the overall glycaemic response to enteral nutrition (blood glucose area under the curve 30 to 270 min, 2,077 ± 145 mmol/l/240 min vs. 2,568 ± 208 mmol/l/240 min; *P*\< 0.02) (Figure [1](#F1){ref-type="fig"}). GLP-1 caused a transient, but nonsustained, suppression of plasma glucagon concentrations (*t*= 30 min, 90 ± 12 pmol/ml vs. 104 ± 10 pmol/ml; *P*\< 0.01) and tended to increase the plasma insulin/blood glucose ratio (between *t*= 0 and 270 min, mean Δinsulin/glucose ratio 5.0 ± 2.0 mU/mmol vs. 2.5 ± 0.9 mU/mmol; *P*= 0.12).

![**Glycaemic response to enteral nutrition is markedly attenuated (\*\* *P*\< 0.02)**.](cc7290-1){#F1}

Conclusion
==========

Acute, exogenous GLP-1 infusion markedly attenuates the glycaemic response to enteral nutrition in the critically ill. Exogenous GLP-1 represents a potentially novel therapy for the management of hyperglycaemia in the critically ill.
